{"id":962736,"date":"2026-05-14T08:24:15","date_gmt":"2026-05-14T12:24:15","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/nuvectis-pharma-inc-to-participate-in-the-h-c-wainwright-4th-annual-bioconnect-investor-conference-at-nasdaq\/"},"modified":"2026-05-14T08:24:15","modified_gmt":"2026-05-14T12:24:15","slug":"nuvectis-pharma-inc-to-participate-in-the-h-c-wainwright-4th-annual-bioconnect-investor-conference-at-nasdaq","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/nuvectis-pharma-inc-to-participate-in-the-h-c-wainwright-4th-annual-bioconnect-investor-conference-at-nasdaq\/","title":{"rendered":"Nuvectis Pharma, Inc. To Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ"},"content":{"rendered":"
\n

Fort Lee, NJ, May 14, 2026 (GLOBE NEWSWIRE) — Nuvectis Pharma, Inc. (NASDAQ: NVCT) (“Nuvectis” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that management will participate in the H.C. Wainwright 4th<\/sup> Annual BioConnect Investor Conference at NASDAQ on Tuesday, May 19, 2026 in New York.<\/p>\n

\n Conference Details: <\/b>
\n
Date: Tuesday, May 19, 2026
Company Presentation: 9:00 \u2013 9:30AM EDT
Presenter: Ron Bentsur, Chairman and Chief Executive Officer of Nuvectis
Webcast Link: here<\/a><\/p>\n

Location: New York, NY<\/p>\n

A webcast of the presentation will be available in the Investors section of Nuvectis\u2019 website at www.nuvectis.com<\/a>.<\/p>\n

\n About Nuvectis Pharma, Inc.<\/b>\n <\/p>\n

Nuvectis Pharma, Inc. is a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology. The Company is developing NXP900, a clinical-stage drug candidate. NXP900 is an oral small molecule inhibitor of the SRC Family of Kinases (SFK), including SRC<\/i> and YES1<\/i>. Its unique mechanism of action enables inhibition of both the catalytic and scaffolding functions of the SRC kinase, providing comprehensive shutdown of the signaling pathway. NXP900 has completed a Phase 1a dose escalation study, a drug-drug interaction study in healthy volunteers and the Phase 1b program is ongoing.<\/p>\n

\n Company Contact:<\/b>\n <\/p>\n

Ron Bentsur
Chairman, Chief Executive Officer and President
rbentsur@nuvectis.com<\/a><\/p>\n

\n Media Relations Contact:<\/b>\n <\/p>\n

Kevin Gardner
LifeSci Advisors
kgardner@lifesciadvisors.com<\/a><\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

Fort Lee, NJ, May 14, 2026 (GLOBE NEWSWIRE) — Nuvectis Pharma, Inc. (NASDAQ: NVCT) (“Nuvectis” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that management will participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ on Tuesday, May 19, 2026 in New York. Conference Details: Date: Tuesday, May 19, 2026Company Presentation: 9:00 \u2013 9:30AM EDTPresenter: Ron Bentsur, Chairman and Chief Executive Officer of NuvectisWebcast Link: here Location: New York, NY A webcast of the presentation will be available in the Investors section of Nuvectis\u2019 website at www.nuvectis.com. About Nuvectis Pharma, Inc. Nuvectis Pharma, Inc. is a … <\/p>\n

Continue reading “Nuvectis Pharma, Inc. To Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-962736","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nNuvectis Pharma, Inc. To Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/nuvectis-pharma-inc-to-participate-in-the-h-c-wainwright-4th-annual-bioconnect-investor-conference-at-nasdaq\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nuvectis Pharma, Inc. To Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Fort Lee, NJ, May 14, 2026 (GLOBE NEWSWIRE) — Nuvectis Pharma, Inc. (NASDAQ: NVCT) (“Nuvectis” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that management will participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ on Tuesday, May 19, 2026 in New York. Conference Details: Date: Tuesday, May 19, 2026Company Presentation: 9:00 \u2013 9:30AM EDTPresenter: Ron Bentsur, Chairman and Chief Executive Officer of NuvectisWebcast Link: here Location: New York, NY A webcast of the presentation will be available in the Investors section of Nuvectis\u2019 website at www.nuvectis.com. About Nuvectis Pharma, Inc. Nuvectis Pharma, Inc. is a … Continue reading "Nuvectis Pharma, Inc. To Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/nuvectis-pharma-inc-to-participate-in-the-h-c-wainwright-4th-annual-bioconnect-investor-conference-at-nasdaq\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-14T12:24:15+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxOTgxOCM3NjAyMjU0IzUwMDA4MjgxNw==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nuvectis-pharma-inc-to-participate-in-the-h-c-wainwright-4th-annual-bioconnect-investor-conference-at-nasdaq\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nuvectis-pharma-inc-to-participate-in-the-h-c-wainwright-4th-annual-bioconnect-investor-conference-at-nasdaq\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Nuvectis Pharma, Inc. To Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ\",\"datePublished\":\"2026-05-14T12:24:15+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nuvectis-pharma-inc-to-participate-in-the-h-c-wainwright-4th-annual-bioconnect-investor-conference-at-nasdaq\\\/\"},\"wordCount\":251,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nuvectis-pharma-inc-to-participate-in-the-h-c-wainwright-4th-annual-bioconnect-investor-conference-at-nasdaq\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcxOTgxOCM3NjAyMjU0IzUwMDA4MjgxNw==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nuvectis-pharma-inc-to-participate-in-the-h-c-wainwright-4th-annual-bioconnect-investor-conference-at-nasdaq\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nuvectis-pharma-inc-to-participate-in-the-h-c-wainwright-4th-annual-bioconnect-investor-conference-at-nasdaq\\\/\",\"name\":\"Nuvectis Pharma, Inc. To Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nuvectis-pharma-inc-to-participate-in-the-h-c-wainwright-4th-annual-bioconnect-investor-conference-at-nasdaq\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nuvectis-pharma-inc-to-participate-in-the-h-c-wainwright-4th-annual-bioconnect-investor-conference-at-nasdaq\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcxOTgxOCM3NjAyMjU0IzUwMDA4MjgxNw==\",\"datePublished\":\"2026-05-14T12:24:15+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nuvectis-pharma-inc-to-participate-in-the-h-c-wainwright-4th-annual-bioconnect-investor-conference-at-nasdaq\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nuvectis-pharma-inc-to-participate-in-the-h-c-wainwright-4th-annual-bioconnect-investor-conference-at-nasdaq\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nuvectis-pharma-inc-to-participate-in-the-h-c-wainwright-4th-annual-bioconnect-investor-conference-at-nasdaq\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcxOTgxOCM3NjAyMjU0IzUwMDA4MjgxNw==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcxOTgxOCM3NjAyMjU0IzUwMDA4MjgxNw==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nuvectis-pharma-inc-to-participate-in-the-h-c-wainwright-4th-annual-bioconnect-investor-conference-at-nasdaq\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Nuvectis Pharma, Inc. To Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nuvectis Pharma, Inc. To Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/nuvectis-pharma-inc-to-participate-in-the-h-c-wainwright-4th-annual-bioconnect-investor-conference-at-nasdaq\/","og_locale":"en_US","og_type":"article","og_title":"Nuvectis Pharma, Inc. To Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ - Market Newsdesk","og_description":"Fort Lee, NJ, May 14, 2026 (GLOBE NEWSWIRE) — Nuvectis Pharma, Inc. (NASDAQ: NVCT) (“Nuvectis” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that management will participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ on Tuesday, May 19, 2026 in New York. Conference Details: Date: Tuesday, May 19, 2026Company Presentation: 9:00 \u2013 9:30AM EDTPresenter: Ron Bentsur, Chairman and Chief Executive Officer of NuvectisWebcast Link: here Location: New York, NY A webcast of the presentation will be available in the Investors section of Nuvectis\u2019 website at www.nuvectis.com. About Nuvectis Pharma, Inc. Nuvectis Pharma, Inc. is a … Continue reading \"Nuvectis Pharma, Inc. To Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/nuvectis-pharma-inc-to-participate-in-the-h-c-wainwright-4th-annual-bioconnect-investor-conference-at-nasdaq\/","og_site_name":"Market Newsdesk","article_published_time":"2026-05-14T12:24:15+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxOTgxOCM3NjAyMjU0IzUwMDA4MjgxNw==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nuvectis-pharma-inc-to-participate-in-the-h-c-wainwright-4th-annual-bioconnect-investor-conference-at-nasdaq\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nuvectis-pharma-inc-to-participate-in-the-h-c-wainwright-4th-annual-bioconnect-investor-conference-at-nasdaq\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Nuvectis Pharma, Inc. To Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ","datePublished":"2026-05-14T12:24:15+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nuvectis-pharma-inc-to-participate-in-the-h-c-wainwright-4th-annual-bioconnect-investor-conference-at-nasdaq\/"},"wordCount":251,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nuvectis-pharma-inc-to-participate-in-the-h-c-wainwright-4th-annual-bioconnect-investor-conference-at-nasdaq\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxOTgxOCM3NjAyMjU0IzUwMDA4MjgxNw==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nuvectis-pharma-inc-to-participate-in-the-h-c-wainwright-4th-annual-bioconnect-investor-conference-at-nasdaq\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/nuvectis-pharma-inc-to-participate-in-the-h-c-wainwright-4th-annual-bioconnect-investor-conference-at-nasdaq\/","name":"Nuvectis Pharma, Inc. To Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nuvectis-pharma-inc-to-participate-in-the-h-c-wainwright-4th-annual-bioconnect-investor-conference-at-nasdaq\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nuvectis-pharma-inc-to-participate-in-the-h-c-wainwright-4th-annual-bioconnect-investor-conference-at-nasdaq\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxOTgxOCM3NjAyMjU0IzUwMDA4MjgxNw==","datePublished":"2026-05-14T12:24:15+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nuvectis-pharma-inc-to-participate-in-the-h-c-wainwright-4th-annual-bioconnect-investor-conference-at-nasdaq\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/nuvectis-pharma-inc-to-participate-in-the-h-c-wainwright-4th-annual-bioconnect-investor-conference-at-nasdaq\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nuvectis-pharma-inc-to-participate-in-the-h-c-wainwright-4th-annual-bioconnect-investor-conference-at-nasdaq\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxOTgxOCM3NjAyMjU0IzUwMDA4MjgxNw==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxOTgxOCM3NjAyMjU0IzUwMDA4MjgxNw=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nuvectis-pharma-inc-to-participate-in-the-h-c-wainwright-4th-annual-bioconnect-investor-conference-at-nasdaq\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Nuvectis Pharma, Inc. To Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/962736","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=962736"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/962736\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=962736"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=962736"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=962736"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}